Pediatric psoriasis: Understanding pathological conditions and advances in treatment
The Journal of Dermatology · 2024-02 · 51 (2) · 185-195
DOI: 10.1111/1346-8138.17049 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The Journal of Dermatology, online erschienen am 17.12.2023. Verfasst von Akimichi Morita und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Geriatric and Environmental Dermatology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan. Hauptthemen laut MEDLINE: Psoriasis, Arthritis, Psoriatic. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novartis Pharma K.K..
Abstract (Originalsprache)
Psoriasis is a long‐lasting skin disease that primarily affects the skin, nails, and joints and is characterized by inflammation. Genetic factors contribute to its development and environmental triggers can worsen symptoms. Pathologically, psoriasis is characterized by uncontrolled keratinocyte proliferation and abnormal differentiation, and histological features include acanthosis with inflammatory cell infiltration and neovascularization. Psoriasis often starts in childhood, with about one‐third of cases beginning during this time. Its prevalence steadily increases from the ages of 1 to 18 years in a linear fashion. Young people with psoriasis often require treatment throughout their childhood and adolescence, and into adulthood. However, prolonged treatment may increase the risk of complications and adverse events, so it is important to adopt an effective treatment approach that minimizes this risk. In addition, psoriasis is often associated with various comorbidities that may place a great burden on the physical and mental health of the children beyond those due to psoriasis itself. To ensure good long‐term health outcomes, individuals with psoriasis should undergo regular screening. Treatment should be provided not only for skin lesions, but also for any comorbidities; however, currently there is not enough evidence on the treatment of pediatric psoriasis and no globally agreed‐on guidelines exist for treating psoriasis in children. This article describes the etiology, clinical symptoms, and disease burden of pediatric psoriasis, the pathological conditions and diagnosis of plaque psoriasis, psoriatic arthritis, and generalized pustular psoriasis, and the available treatments for these conditions in Japan.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Geriatric and Environmental Dermatology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
- Department of Dermatology, Nippon Medical School Hospital, Tokyo, Japan.
ORCID-Profile: Akimichi Morita, Hidehisa Saeki
Förderung
- Novartis Pharma K.K.
Zitieren
APA
Morita, A., & Saeki, H. (2024). Pediatric psoriasis: Understanding pathological conditions and advances in treatment. The Journal of Dermatology, 51(2), 185-195. https://doi.org/10.1111/1346-8138.17049
Vancouver
Morita A, Saeki H. Pediatric psoriasis: Understanding pathological conditions and advances in treatment. The Journal of Dermatology. 2024;51(2):185-195. doi:10.1111/1346-8138.17049
BibTeX
@article{Morita2024,
author = {Morita, Akimichi and Saeki, Hidehisa},
title = {Pediatric psoriasis: Understanding pathological conditions and advances in treatment},
journal = {The Journal of Dermatology},
year = {2024},
volume = {51},
number = {2},
pages = {185--195},
doi = {10.1111/1346-8138.17049}
}
EUVIMED